Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment in hypertensive patients with known comorbidities: pooled analysis of six prospective real-world studies including 11,999 patients

Nimer Alkhatib, Diana Sun, Kris Denhaerynck, Dina Hamarneh, Yoleen Van Camp, Lorenzo Villa, Heidi Brié, Stefaan Vancayzeele, Karen MacDonald, Ivo Abraham

Research output: Contribution to journalArticlepeer-review

Abstract

Aims: Six prospective real-world studies of antihypertensive treatment with valsartan-centric regimens were pooled to: (1) examine the effectiveness of ∼90 days of second- or later-line valsartan treatment in hypertensive patients with known comorbidities; and (2) identify physician- and patient-related determinants associated with systolic (SBP) and diastolic blood pressure (DBP) outcomes in these patients. Methods and materials: A pooled analysis was performed of an evaluable sample of 11,999 hypertensive patients with known comorbidities treated ∼90 days with valsartan-centric regimens. We applied hierarchical linear and logistic regression models to identify determinants of blood pressure (BP) outcomes and a potential physician class effect. Results: Valsartan regimens resulted in mean (SD) SBP and DBP reductions of 18.0 (15.8) mmHg and 9.5 (10.1) mmHg, respectively, at ∼90 days, yielding SBP, DBP and combined SBP/DBP control rates of 44.0%, 67.2% and 39.3%, respectively. About a quarter of the variance in 90 day BP values was attributable to a physician class effect. BP outcomes declined with physicians’ increasing years in practice and being male. At the patient level, BP outcomes declined with SBP and DBP at diagnosis; diabetes; higher cholesterol and BMI; lower valsartan and hydrochlorothiazide (HCTZ) doses; and concomitant anti-hypertensives. Older age was associated with improved DBP. A proxy of physician vigilance, cardiovascular disease history, was associated with improved BP outcomes, as were patient adherence and higher doses of valsartan in combination with HCTZ. Conclusions: Valsartan-centric regimens have significant BP lowering benefits in this pooled sample of patients with known comorbidities. Many observed determinants of BP outcomes are modifiable or manageable.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalCurrent Medical Research and Opinion
Volume37
Issue number1
DOIs
StatePublished - 2021

Keywords

  • Angiotensin II receptor blockers
  • antihypertensive agents
  • blood pressure
  • determinant factors
  • epidemiologic studies
  • hypertension
  • logistic models
  • medication adherence
  • valsartan

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment in hypertensive patients with known comorbidities: pooled analysis of six prospective real-world studies including 11,999 patients'. Together they form a unique fingerprint.

Cite this